BioTech Pharma
HomeResourcesQualification Lots and Acceptance Criteria Before Scale-Up
Procurement

Qualification Lots and Acceptance Criteria Before Scale-Up

Published August 16, 2026 8 min read1,410 words

Key Takeaways

  • Qualify the route you will actually rely on, at the largest representative scale you can, with the documentation routine lots will carry.
  • Write acceptance criteria and decision rules before the material arrives so the standard cannot quietly bend to fit the data.
  • Run both an analytical review against specification and an application review in your real downstream use.
  • Record the scale authorization and the changes that would trigger re-qualification, such as a new route, site, salt form, or larger scale.

Why the first big order is the wrong time to learn

A material that performed well in a few research vials can behave differently once the route is scaled and the process is run to fill hundreds of units. Impurity profiles shift, a counterion ratio drifts, an assay that was never stressed at small scale starts to show variability. If the first time you discover this is inside a large recurring order, you have already paid for material you may not be able to use.

A qualification lot exists to move that discovery earlier and make it cheap. It is a deliberately structured purchase whose purpose is not to stock your program but to answer a question: does material made by the route you intend to rely on meet the criteria your application actually needs? The discipline that makes the answer trustworthy is writing down the criteria before the data exists.

The economics are worth being blunt about. A qualification lot costs real money and real time, and it does not directly advance the work; it only reduces the risk of a much larger commitment. That trade is worth making whenever the downstream order is large, hard to unwind, or on a schedule that leaves no room to recover from a bad first production lot. For a small one-off purchase, the ceremony is not worth it, and pretending otherwise wastes effort.

Make the lot representative of what you will buy

A qualification lot only predicts future supply if it is made the way future supply will be made. That means the same synthetic route, the same purification approach, the same salt form, and ideally the same equipment class and site the supplier will use at production scale. A lot made by a boutique small-scale method tells you little about a lot that will later come off a different line.

Scale itself is a variable to think about explicitly. You rarely qualify at full target scale, so decide which attributes are scale-sensitive and worth pushing toward representative conditions, and which are not. Where a full-scale run is impractical, agree with the supplier on the largest representative scale that is feasible, and document why it stands in for the eventual volume.

Ask for the same deliverables you will require in routine supply, including the certificate of analysis and supporting data. If the qualification lot arrives with richer documentation than routine lots will, you have qualified a paperwork exercise rather than the ongoing supply.

Write the protocol before material arrives

The protocol is a short written document that states, in advance, what you will test, how, and what result counts as a pass. It should name each attribute, the method and the sample handling, the number of units or replicates, and the person or role responsible for the decision. Writing it before the lot arrives is what prevents the criteria from quietly relaxing to match whatever showed up.

Keep the protocol proportionate. A qualification lot is not a validation exercise, and loading it with tests you will never run routinely wastes material and time. Include the attributes that would actually stop you from using the material and the ones most likely to move with scale, and leave the rest to routine monitoring.

Decide the sample plan and the quantity you will consume in testing before you order, because that consumption reduces the material left for the confirmatory application work. If the analytical panel eats most of a small qualification lot, you will not have enough left to run the functional check that actually matters, and you will have qualified the specification without qualifying the use. Order the qualification lot large enough to survive its own testing.

Two reviews: analytical and application

Qualification has two halves that people often collapse into one. The analytical review asks whether the material meets its specification: identity confirmed, purity within limits, content in range, and the safety-adjacent attributes your use requires all inside their bounds. This is the review that a certificate of analysis largely supports.

The application review asks a different question: does the material work in your hands, in your assay or process, at the performance you need? A lot can pass every analytical limit and still underperform in a functional readout because of an attribute you did not specify. Running the qualification lot through the real downstream use, not just the analytical panel, is what turns qualification from a compliance ritual into a genuine predictor.

When the two reviews disagree, the disagreement is the most valuable output of the whole exercise. A lot that passes analytically but fails in application is telling you that your specification is missing an attribute; a lot that struggles analytically but performs well is telling you a limit may be tighter than your use requires. Either finding lets you correct the specification before it is frozen into a recurring contract, which is a far better time to learn it than during routine supply.

Decision rules, not judgment calls

Acceptance criteria should be written as rules that can be applied without re-litigating them under pressure. For each attribute, state the limit and what happens on a result outside it: reject, investigate, or accept with a documented rationale. Distinguish attributes that are pass-or-fail from those where a marginal result triggers a defined next step such as a repeat test or a supplier conversation.

Decide in advance how you handle a single failing attribute in an otherwise strong lot. A blanket rule that any deviation fails the lot is simple but can waste good material; a rule that allows documented, reviewed exceptions is more flexible but must name who can approve one. Either choice is defensible. What is not defensible is inventing the rule after seeing the result you dislike.

  • Every attribute has a written limit and a defined action for a result outside it.
  • Marginal and failing results follow different paths, both decided in advance.
  • Any accept-with-rationale exception names the role authorized to grant it.
  • The application readout, not only the specification, contributes to the decision.

Comparability against your reference

Qualification is often less about absolute numbers and more about comparability: is the new lot equivalent to a reference you already trust? Choose the reference deliberately, whether it is a prior lot that performed well or a characterized in-house standard, and compare the qualification lot against it for the attributes that matter to your use.

Comparability thinking, familiar from stability and lifecycle guidance for biological and complex products, helps you decide how much change is tolerable. Small differences in an impurity profile may be acceptable if the functional performance holds; a shift in the main species is a different matter. State which differences you will treat as noise and which as signal before you plot the data.

A single qualification lot cannot tell you how much a supplier's output will vary from lot to lot; it only tells you that one lot met the bar. Be honest about that limit. If lot-to-lot consistency is critical to your program, plan to confirm it across the first few production lots rather than assuming a single passing qualification lot has settled the question, and set the routine monitoring that will catch a drift early.

Authorizing the scale-up

When the lot passes, the authorization to scale should be an explicit, recorded decision rather than a drift into ordering more. Record what was qualified, the route and scale it represents, the criteria it met, any exceptions granted, and the volume and cadence the authorization covers. That record is what you point to if a later production lot disappoints.

Tie the authorization to conditions that would require re-qualification: a change of synthetic route, site, salt form, or a scale increase beyond the range you qualified. Suppliers change processes for legitimate reasons, and a clear re-qualification trigger keeps a quiet improvement on their side from becoming a surprise on yours. A functioning pharmaceutical quality system treats such changes as controlled events, and your supply arrangement should mirror that expectation.

References & further reading

These sources provide technical context for the concepts discussed above. The article is educational and is not a substitute for a program-specific specification or qualified scientific review.

  1. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products U.S. Food and Drug Administration (reference 1, opens in a new tab)
  2. ICH Q10 Pharmaceutical Quality System — Scientific guideline European Medicines Agency (reference 2, opens in a new tab)
  3. Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products U.S. Food and Drug Administration (reference 3, opens in a new tab)
  4. Process Validation: General Principles and Practices U.S. Food and Drug Administration (reference 4, opens in a new tab)
  5. 〈1503〉 Quality Attributes of Synthetic Peptide Drug Substances United States Pharmacopeia (USP–NF) (reference 5, opens in a new tab)